You are here

Trendlines, B Braun firm up deal to invest in healthcare incubator

39782219 - 08_09_2016 - rbtrendlines.jpg
(From left) Trendlines Medical Singapore chief executive Eric Loh, Trendlines chairman and chief executive D. Todd Dollinger and B. Braun Singapore managing director Lam Chee Hong.

SINGAPORE-LISTED Trendlines Group and Germany-based B Braun have executed a definitive investment and cooperation agreement to jointly invest in Trendlines Medical Singapore (TMS), a platform to invest in and incubate early-stage healthcare companies with a focus on Singapore and the region.

B Braun will take a minority stake of 20.74 per cent in TMS, with Trendlines holding the majority 79.26 per cent interest.

Anna Maria Braun, president of B Braun Asia-Pacific and a member of the B Braun management board, and Boris Hofmann, director of business development of B Braun's Aesculap division, are joining the TMS board of directors. Todd Dollinger, chairman and CEO of Trendlines, is the chairman of TMS.

TMS is Trendlines' first incubator outside of Israel.

Market voices on:

B Braun will support the commercialisation of TMS's portfolio companies by providing medtech-related expertise, such as regulations, medical and scientific affairs, and marketing and sales.

Mr Dollinger said in September when the joint investment with B Braun was unveiled, that though its focus is in medtech, TMS will not rule out investing in other tech types.